tetano
Editor, Senior Moderator
Respir Investig
. 2023 Jan 12;61(2):153-156.
doi: 10.1016/j.resinv.2022.12.006. Online ahead of print.
IFN-λ3 and CCL17 as predictors of disease progression in patients with mild to moderate COVID-19: A cohort study in a real-world setting
Yasuhito Sekimoto[SUP] 1 [/SUP], Mitsuaki Sekiya[SUP] 2 [/SUP], Shuko Nojiri[SUP] 3 [/SUP], Eri Hayakawa[SUP] 2 [/SUP], Yoshihiro Masui[SUP] 2 [/SUP], Manabu Tajima[SUP] 2 [/SUP], Koichi Nishino[SUP] 2 [/SUP], Yuji Nishizaki[SUP] 4 [/SUP], Kazuhisa Takahashi[SUP] 5 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) has overwhelmed hospitals worldwide. In Japan, serum interferon lambda 3 (IFN-λ3) and C-C motif ligand (CCL) 17 levels have been used as predictive markers for disease progression to severe COVID-19. However, the relationship between these predictive markers and the disease progression of COVID-19 has not been well evaluated. We retrospectively evaluated the patient characteristics, serum IFN-λ3 and CCL17 levels, and comorbidities of 92 patients with mild (n = 20) and moderate (n = 72) COVID-19 who were hospitalized in our institution. The results of the multivariable analysis showed that the positive rates of IFN-λ3, CCL17, and the combination of these markers were significantly elevated in patients with progressed COVID-19. Furthermore, patients who were negative for both markers did not experience disease progression. This study illustrates the importance of measuring these markers to predict disease severity and progression in patients with COVID-19.
Keywords: CCL17; COVID-19; IFN-λ3; Predictive marker.
. 2023 Jan 12;61(2):153-156.
doi: 10.1016/j.resinv.2022.12.006. Online ahead of print.
IFN-λ3 and CCL17 as predictors of disease progression in patients with mild to moderate COVID-19: A cohort study in a real-world setting
Yasuhito Sekimoto[SUP] 1 [/SUP], Mitsuaki Sekiya[SUP] 2 [/SUP], Shuko Nojiri[SUP] 3 [/SUP], Eri Hayakawa[SUP] 2 [/SUP], Yoshihiro Masui[SUP] 2 [/SUP], Manabu Tajima[SUP] 2 [/SUP], Koichi Nishino[SUP] 2 [/SUP], Yuji Nishizaki[SUP] 4 [/SUP], Kazuhisa Takahashi[SUP] 5 [/SUP]
Affiliations
- PMID: 36682084
- DOI: 10.1016/j.resinv.2022.12.006
Abstract
Coronavirus disease 2019 (COVID-19) has overwhelmed hospitals worldwide. In Japan, serum interferon lambda 3 (IFN-λ3) and C-C motif ligand (CCL) 17 levels have been used as predictive markers for disease progression to severe COVID-19. However, the relationship between these predictive markers and the disease progression of COVID-19 has not been well evaluated. We retrospectively evaluated the patient characteristics, serum IFN-λ3 and CCL17 levels, and comorbidities of 92 patients with mild (n = 20) and moderate (n = 72) COVID-19 who were hospitalized in our institution. The results of the multivariable analysis showed that the positive rates of IFN-λ3, CCL17, and the combination of these markers were significantly elevated in patients with progressed COVID-19. Furthermore, patients who were negative for both markers did not experience disease progression. This study illustrates the importance of measuring these markers to predict disease severity and progression in patients with COVID-19.
Keywords: CCL17; COVID-19; IFN-λ3; Predictive marker.